Outcome Capital

The article discusses Big Pharma’s need to acquire new products and how acquisitions or public offerings can reward investors in small biotech companies.

The article discusses Big Pharma’s need to acquire new products and how acquisitions or public offerings can reward investors in small biotech companies. It also describes a force creating difficulties in biotech boardrooms.

Big pharma flight from anti-infective R&D will create significant challenges for early-stage biotech companies seeking to develop novel and much needed drugs in this sector, as opportunities for partnerships, joint R&D relationships, and merger/acquisition transactions are diminishing.

Partnerships and the move to value dominated the chatter at the BIO International Convention's 25th annual partnering meeting on Monday in the life science hub of Boston.

In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital-efficient manner.

Outcome Capital, a Boston-based life sciences investment banking and strategic advisory firm, seeks an analyst or senior analyst to join its team.

Athersys, which is developing MultiStem for critical care, entered a warrant exercise inducement offer to raise up to approximately $3.9 million and received a first tranche payment of $1.5 million.

Outcome Capital seeks a managing director for its Biotechnology practice. The role includes tracking public and private biotechnology companies, managing deal teams and originating deals.

Premium Life Sciences and Healthcare Advisory and Strategic Investment Banking Led by Industry Veterans Ushering Technologies From Bench To Bedside

Outcome Capital says it provides this notice to customers or investors to disclose its policy for retaining personal information under SEC guidelines.